Given the increasing incidence of diabetes and heart failure as well as the impaired prognosis if both comorbidities come together, treatment of these patients requires an interdisciplinary, evidence-based approach to reduce morbidity and mortality in this high-risk population.

The risk of heart failure significantly increased in association with less selective sorafenib (OR: 3.53), pazopanib (OR: 3.10), and sunitinib (OR: 2.65).

This review provide information’s on the preclinical and clinical pharmacology of this new drug class and will discuss its future clinical applications in patients with cardiorenal disease.

Participants in the intensive-therapy group with high baseline HbA1c and cumulative HbA1c exposure had a significantly higher risk of primary outcome, all-cause mortality, and CV-related death.

Peripherally measured NPY is an independent predictor of all cause and CV death even after adjustment for other prognostic variables, including BNP.

No significant differences were observed between MHT users and controls regarding primary outcomes of nonfatal MI, CV-related death, or stroke. No differences in frequency of angina, HF, and TIAs were observed.

SGLT2 inhibitors in patients with diabetes mellitus have been efficacious for glycemic control, renal protection, decreasing the risk of atherosclerotic cardiovascular disease events, and reducing cardiac mortality.

A network meta-analysis revealed that empagliflozin users with diabetes experienced a lower risk of dying from any cause than those using dapagliflozin.

SGLT2 inhibitors are cardioprotective in a wide spectrum of eGFR rates, although data for patients with HF with respect to the UAC ratio remain limited.

Plasma FABP4 was identified as the main heart failure (HF) predictor. Higher levels of adiposity markers are associated with atrial fibrillation (AF) or HF and higher stretch and fibrosis markers with combined AF and HF.

These study results indicated a noteworthy effect of cryoablation in mitigating atrial fibrillation (AF) recurrence, alongside a success rate, denoted by freedom from AF at 1 and 2 years postprocedure.

In patients with heart failure and preserved ejection fraction, abnormal sodium burden was an independent predictor long-term any-cause mortality and HF hospitalization.

Researchers from the Middle East studied the utilization patterns of CVD medications in patients with T2DM for 4 years. Women had the highest rate of utilization of CVD medications across the entire study range. Utilization patterns of medications recommended for prevention and treatment of CVD in diabetes were observed to be the highest.

Comorbidities have significantly negative pooled effects on HF patient health outcomes, especially in regard to the prognostic health outcomes. Clinicians should carefully identify and manage these conditions when implementing HF interventions to improve prognostic outcomes.

Researchers engaged key stakeholders in human-centered design sessions to identify challenges in guideline-directed medical therapies optimization posthospitalization and inform the development of a digital toolkit aimed at optimizing HF therapy. Several themes emerged from the clinician, patient, and caregiver sessions on challenges to...

EMPA causes a switch in metabolism away from glucose oxidation toward increased ketone utilisation in the rat heart, thereby improving function and energetics both during ischaemia and recovery during reperfusion. This preference of ketone utilisation over glucose was observed under conditions of constant supply of substrate, suggesting that...

This real-world study of empagliflozin use in the inpatient setting found no significant differences in safety endpoints between empagliflozin and other oral antihyperglycemic agents. Larger-scale studies need to be performed before the use of empagliflozin can be routinely recommended in the inpatient setting.